Announcements Trials
Browse Landscape

Phase

Phase 1/2 1Phase 1 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Conditions

Precursor Cell Lymphoblastic Leukemia-Lymphoma 72Multiple Myeloma 70Leukemia, Myeloid, Acute 70Lymphoma, Large B-Cell, Diffuse 61Lymphoma, Non-Hodgkin 58Leukemia, Lymphocytic, Chronic, B-Cell 57Lymphoma 56Melanoma 52Leukemia 52Breast Neoplasms 49Burkitt Lymphoma 48Myelodysplastic Syndromes 44Recurrence 41Lymphoma, Follicular 41Lymphoma, B-Cell 38Lymphoma, Mantle-Cell 37Ovarian Neoplasms 32Neuroblastoma 32Lymphoma, B-Cell, Marginal Zone 27Sarcoma 26Neoplasms 26Carcinoma, Non-Small-Cell Lung 25Hodgkin Disease 24Neoplasm Metastasis 23Triple Negative Breast Neoplasms 18Carcinoma, Renal Cell 18Neoplasms, Plasma Cell 17Hematologic Neoplasms 17Leukemia, Myelomonocytic, Chronic 16Colorectal Neoplasms 16

Interventions

Nivolumab 8Paclitaxel 6Sirolimus 5Bevacizumab 5temsirolimus 4Pemetrexed 4Ipilimumab 4Docetaxel 4Carboplatin 4ARRY-334543 4Gemcitabine 3Erlotinib Hydrochloride 3olaparib 2linrodostat 2apatinib 2anlotinib 2abemaciclib 2Vorinostat 2Sunitinib 2Magnetic Resonance Spectroscopy 2Irinotecan 2Everolimus 2Doxorubicin 2Dasatinib 2Chlorogenic Acid 2Cetuximab 26-(6-(1-methyl-1H-pyrazol-4-yl)-(1,2,4)triazolo(4,3-b)pyridazin-3-ylsulfanyl)quinoline 2vorolanib 1vistusertib 1trametinib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1 × Advanced Cancer × Cyclophosphamide × Clear all
NCT02383212 2020-01-27

Study of REGN2810 (Anti-PD-1) in Patients With Advanced Malignancies

Regeneron Pharmaceuticals

Phase 1 Completed
398 enrolled

Advanced Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡